文献速递肝病

维持端粒可阻止肝星状细胞转分化及肝纤维化发生

Upholding telomeres prevents hepatic stellate cell transdifferentiation and liver fibrogenesis.
PubMed 文献 · Hepatology · 2026-10-14

该研究在小鼠CCl4或BDL肝纤维化模型中,通过HSC特异性过表达TERT或TPP1(Acd)以及腹腔注射TELODIN,发现端粒功能障碍介导HSC转分化,靶向稳定TPP1可减轻实验性肝纤维化。

要点

  • HSC特异性过表达TERT或TPP1可抑制HSC活化、增殖和转分化,减轻肝纤维化。
  • TELODIN腹腔注射稳定TPP1、减少端粒功能障碍,维持HSC静息状态并减轻纤维化。
  • 端粒功能障碍是HSC转分化为促纤维化肌成纤维细胞的关键机制。

核心结论

  • 端粒功能障碍介导实验性肝纤维化过程中HSC的转分化。
  • 增加端粒酶活性或TPP1介导的端粒酶募集与激活可减轻HSC介导的纤维化。
  • 药理学给予TELODIN通过恢复HSC端粒稳态有效减轻实验性肝纤维化。

研究设计与样本

  • 研究在CCl4处理或胆管结扎(BDL)的小鼠中建立肝纤维化,并进行组织与分子病理及生化表征。
  • 通过流式细胞术分离HSC;构建HSC特异性过表达TERT或Acd(编码shelterin组分TPP1)的小鼠。
  • 部分小鼠腹腔注射端粒功能障碍抑制剂TELODIN(稳定端粒酶激活剂TPP1的D-氨基酸八肽)。

主要发现

  • HSC特异性TERT表达通过抑制HSC活化、增殖和转分化减轻肝纤维化。
  • HSC特异性TPP1过表达通过防止端粒功能障碍和缩短减轻肝纤维化。
  • TELODIN腹腔给药拮抗肝纤维化发生并维持HSC静息状态。
  • 机制上,TELODIN稳定TPP1、减少端粒功能障碍并降低HSC向促纤维化肌成纤维细胞的转分化。

临床怎么用

  • 靶向端粒维持(如稳定TPP1或增强端粒酶活性)可能成为抗肝纤维化的治疗策略。
  • TELODIN在实验性肝纤维化中显示药理学可行性,但尚未报告人体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AIMS: Hepatic stellate cells (HSCs) are principal drivers of liver cirrhosis. Whether and how telomere dysfunction affects HSC function remain unclear. This study was undertaken to investigate the role of telomere maintenance in HSCs during fibrogenesis and to evaluate its therapeutic potential by genetic and pharmacological means. APPROACH RESULTS: Liver fibrosis was established in mice treated with carbon tetrachloride (CCl4) or bile duct ligation (BDL), and characterized by tissue and molecular pathology and biochemistry, followed by HSC isolation using flow cytometry. Animals were engineered for HSC-specific overexpression of the telomerase reverse transcriptase (TERT) gene or Acd (encoding the shelterin component TPP1). Alternatively, mice were intraperitoneally injected with telomere dysfunction inhibitor (TELODIN), a D-amino acid octapeptide that stabilizes the telomerase activator TPP1. HSC-specific TERT expression alleviated hepatic fibrosis by suppressing HSC activation, proliferation, and transdifferentiation. Likewise, HSC-specific TPP1 overexpression mitigated hepatic fibrosis by preventing telomere dysfunction and shortening. Pharmacological stabilization of TPP1 by intraperitoneal administration of TELODIN counteracted hepatic fibrogenesis while maintaining HSC quiescence. Mechanistically, TELODIN stabilized TPP1, reduced telomere dysfunction, and decreased HSC transdifferentiation into profibrotic myofibroblasts. CONCLUSIONS: Telomere dysfunction mediates HSC transdifferentiation during experimental hepatic fibrogenesis. Targeted interventions - that increase telomerase activity or TPP1 mediated telomerase recruitment and activation - alleviate HSC-mediated fibrosis. Pharmacological administration of TELODIN effectively attenuates experimental liver fibrosis by restoring telomere homeostasis in HSCs.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang L, Li H, Yang L, et al. Upholding telomeres prevents hepatic stellate cell transdifferentiation and liver fibrogenesis. Hepatology. 2026. PMID: 42873809. doi:10.1097/HEP.0000000000001889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。